Insulet Signs Agreement To Provide New Drug Delivery Device for Biotech Firm Amgen

As the healthcare industry continues to adjust to a new landscape, new partnerships and collaborations will be key to future success.

The last few years have seen examples of collaboration all across the spectrum. For instance, in 2009 Medtronic announced that it was entering into a strategic marketing partnership with Eli Lilly to provide solutions for managing diabetes. In 2010, Mayo Clinic said it was working with health insurance firm Medica on a pay-for-performance model whereby Medica would reward the health provider for keeping a preselected group of patients healthy. In 2013, GlaxoSmithKline announced in April that it was partnering with Avalon Ventures, a venture capital firm to fund up to 10 startup biotech firms.

On Tuesday there was yet another example of collaboration between different players in the healthcare spectrum. Medtech firm Insulet, known for its tubing-free, and relatively painless insulin delivery system, announced that it has signed a five-year commercial agreement with Amgen, whereby Insulet would deliver a delivery device for Amgen’s biologics-based medicines.

The delivery device will be based on Insulet’s Omnipod insulin pump therapy, a tubeless insulin pump that made up of two components and fully-automated cannula insertion. Since the company was founded in 2000, Insulet, a public company, has produced 25 million OmniPods.

"We are thrilled to advance our collaboration with Amgen to supply this version of our technology," said Duane DeSisto, President and Chief Executive Officer of Insulet, in a news release. As the healthcare industry continues to adjust to a new landscape, new partnerships and collaborations will be key to future success.
The last few years have seen examples of collaboration all across the spectrum. For instance, in 2009 Medtronic announced that it was entering into a strategic marketing partnership with Eli Lilly to provide solutions for managing diabetes. In 2010, Mayo Clinic said it was working with health insurance firm Medica on a pay-for-performance model whereby Medica would reward the health provider for keeping a preselcted group of patients healthy. In 2013, GlaxoSmithKline announced in April that it was partnering with Avalon Ventures, a venture capital firm to fund up to 10 startup biotech firms.

On Tuesday there was yet another example of collaboration between different players in the healthcare spectrum. Medtech firm Insulet, known for its tubing-free, and relatively painless insulin delivery system, announced that it has signed a five-year commercial agreement with Amgen, whereby Insulet would deliver a delivery device for Amgen’s biologics-based medicines.

The delivery device will be based on Insulim’s Omnipod insulin pump therapy, a tubeless insulin pump that made up of two components and fully-automated cannula insertion. Since the company was founded in 2000, Insulet, a public company, has produced 25 million OmniPods.

"We are thrilled to advance our collaboration with Amgen to supply this version of our technology," said Duane DeSisto, President and Chief Executive Officer of Insulet, in a news release.

[Image Courtesy of Insulet]

 -- By Arundhati Parmar, Senior Editor, MD+DI
[email protected]